GAINESVILLE, Fla., CAMBRIDGE, Mass. and EDINBURGH, Scotland, Dec. 9, 2015 -- Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare eye diseases, and Synpromics Limited, a leading synthetic promoter development company backed by Calculus Capital, today announced they have entered into a broad, multi-target collaboration agreement.